Get started
Author

Jonas Buchloh

Observed names: Buchloh, Jonas, J Buchloh
Observed institutions: German Cancer Research Center, Heidelberg University, Universitätsmedizin Göttingen, University Medical Centre Mannheim, Medizinische Fakultät Mannheim, University of Göttingen
ORCID: 0000-0002-9820-3054
Observed ORCID: 0000-0002-9820-3054
OpenAlex ID: A5041237458
Combined MEK and PARP inhibition enhances radiation response in rectal cancer
2025 · Qiyun Xiao, Julian E. Riedesser, et al. · Cell Reports Medicine · 10
Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer
2025 · Jonas Buchloh, Melanie Spitzner, et al. · United European Gastroenterology Journal · 6
PDF
Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations
2021 · Malte Simon, Sadaf S. Mughal, et al. · Journal of Translational Medicine · 6
PDF
Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer
2026 · Maximilian Hellkamp, Simon Gertken, et al. · Journal of Experimental & Clinical Cancer Research · 1
An organoid platform reveals MEK-PARP co-targeting to enhance radiation response in rectal cancer
2024 · Qiyun Xiao, Julian E. Riedesser, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
Correction to: Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations
2022 · Malte Simon, Sadaf S. Mughal, et al. · Journal of Translational Medicine · 1
PDF
Figure S1 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure 4 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure S5 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure 6 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure 5 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure 2 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure S2 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure S3 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure 1 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Data from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Table S1 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure S4 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Table S2 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure 3 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Figure S6 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al.
Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026 · Valentina Spielmann, Jonas Buchloh, et al. · Cancer Research Communications
Additional file 6 of Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer
2026 · Hellkamp, Maximilian, Gertken, Simon, et al. · Figshare
Additional file 8 of Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer
2026 · Hellkamp, Maximilian, Gertken, Simon, et al. · Figshare
Additional file 1 of Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer
2026 · Hellkamp, Maximilian, Gertken, Simon, et al. · Figshare
Works count: 40
Citation count: 25
H-index: 3
I10-index: 1
Year
Topic
Type